AIPher
Beijing, China
◆ Total Raised
$14.9M
◆ Stage
seed
◆ Location
Beijing, China
◆ Founded
2026
◆ About AIPher
AI-native pharmaceutical company using AI agents for drug discovery and R&D.
◆ What sets it apart
它将AI基础模型与药物研发智能体结合，试图把药物发现从单点工具优化升级为端到端、全流程的智能决策系统。
◆ Sectors
BiotechDrug DiscoveryAI Frontier Models
◆ Business
ModelSaaS
Customer药物研发与创新药相关的合作方，包括制药公司、科研机构及药物研发生态伙伴
◆ Notable
- 2026年完成亿元天使轮融资
- 融资由襄禾资本领投，智谱旗下星连资本及产业基金跟投
- 其核心技术来源于清华大学智能产业研究院（AIR）团队
- DrugCLIP相关技术曾发表于Science
◆ Backing funds on Raise
- Xinglian Capitalseed
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does AIPher do?
AI-native pharmaceutical company using AI agents for drug discovery and R&D.
Where is AIPher based?
AIPher is based in Beijing, China, founded in 2026.
How much has AIPher raised?
AIPher has raised $14.9M in tracked funding and is currently at the seed stage.
Who has invested in AIPher?
Investors in AIPher include 襄禾资本, 星连资本 and 某知名产业基金.